Prognostic Value of Mitotic Index and Bcl2 Expression in Male Breast Cancer

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Lacle, Miangela M ^a   van der Pol, Carmen ^a   Witkamp, Arjen ^a   van der Wall, Elsken ^a   van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALE BREAST; MITOSIS INDEX; MITOSIS RATE; PREDICTIVE VALUE; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE ARRAY ANALYSIS;

EID: 84875654495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060138     Document Type: Article

References (34)

1. Speirs V, Shaaban A, (2009) The rising incidence of male breast cancer. Breast Cancer Res Treat 115: 429-430.
2. Weber-Chappuis K, Bieri-Burger S, Hurlimann J, (1996) Comparison of Prognostic Markers Detected by Immunohistochemistry in Male and Female Breast Carcinomas. Eur J Cancer 32A(10): 1686-1692.
3. Shaaban AM, Ball GR, Brannan RA, Cserni G, Di Benedetto A, et al. (2012) A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 133(3): 949-958.
4. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, et al. (2012) Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 25(3): 398-404.
5. Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MC, de Bruin PC, et al. (2012). Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res Jul 5;14(4): R101 [Epub ahead of print].
6. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, et al. (2012) Fibrotic focus and hypoxia in male breast cancer. Mod Pathol 25(10): 1397-404.
7. Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MC, de Bruin PC, et al. (2012) Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 135(1): 49-58.
8. Van Diest PJ, van der Wall E, Baak JP, (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57 (7): 675-681.
9. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, et al. (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23: 5993-6001.
10. Pich A, Margaria E, Chiusa L, (1994) Proliferative Activity is a Significant Prognostic Factor in Male Breast Carcinoma. Am J Pathol 145(2): 481-489.
11. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
12. Abdel-Fatah T, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, et al. (2010) Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol 222: 388-399.
13. Temmim L, Luqmani YA, Jarallah M, Juma I, Mathew M, (2001) Evaluation of prognostic factors in male breast cancer. Breast 10(2): 166-175.
14. Pich A, Margaria E, Chiusa L, (1998) Bcl-2 expression in male breast carcinoma. Virchows Arch 433: 229-35.
15. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, et al. (1998) Molecular Markers in Male Breast Carcinoma. Cancer 83: 1947-1955.
16. Central Committee on Research involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek) (text in Dutch). Available: http://www.ccmo-online.nl/main.asp?pid=10&sid=30&ssid=51.
17. van Diest PJ, (2002) No consent should be needed for using leftover body material for scientific purposes. BMJ 325: 648-51.
18. Tavassoli FA, Devilee P (2003) Tumours of the Breast and Female Genital Organs. World Health Organization Classification of tumours; Pathology and Genetics. Lyon: International Agency for Research on Cancer. 432 p.
19. Van Diest PJ, Baak JP, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, et al. (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23(6): 603-607.
20. Baak JP, van Diest PJ, Ariens AT, van Beek MW, Bellot SM, et al. (1989) The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract 185: 664-670.
21. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, et al. (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12: 2468-2475.
22. McDonnell TJ, Korsmeyer SJ, (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349: 254-256.
23. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, et al. (1994) Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 54: 3714-3717.
24. Zinkel S, Gross A, Yang E, (2006) BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13: 1351-1359.
25. Hwang K, Woo Woo J, Shin HC, Kim HS, Ahn SK, et al. (2012) Prognostic infl{ligature}uence of BCL2 expression in breast cancer. Int J Cancer 131(7) E1109-E1119 [Epub ahead of print].
26. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, et al. (2010) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br. J. Cancer 103: 668-675.
27. Callagy GM, Webber MJ, Pharoah PD, Caldas C, (2008) Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 8: 153-162.
28. Trere D, Montanaro L, Ceccarelli C, Barbieri S, Cavrini G, et al. (2007) Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol 18: 1004-1014.
29. Jalava PJ, Collan YU, Kuopio T, Juntti-Patinen L, Kronqvist P, (2000) Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N+ breast cancer patients. Anticancer Res 20: 1213-1219.
30. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, et al. (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504.
31. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, et al. (1994) The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 424: 47-51.
32. V Bhargava V, Kell DL, van de Rijn M, Warnke RA (1994) Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 45, 535-540.
33. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, et al. (2002) Male Breast Carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Path 15: 853-861.
34. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, et al. (2012) Immunophenotyping of male breast cancer. Histopathology doi:10.1111/j.1365-2559.2012.04330.x. [Epub ahead of print].